AR115296A1 - Heterocíclicos inhibidores de mat2a y métodos de uso para el tratamiento del cáncer - Google Patents
Heterocíclicos inhibidores de mat2a y métodos de uso para el tratamiento del cáncerInfo
- Publication number
- AR115296A1 AR115296A1 ARP190103901A ARP190103901A AR115296A1 AR 115296 A1 AR115296 A1 AR 115296A1 AR P190103901 A ARP190103901 A AR P190103901A AR P190103901 A ARP190103901 A AR P190103901A AR 115296 A1 AR115296 A1 AR 115296A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- independently selected
- halo
- group
- aryl
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 3
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 101000947881 Homo sapiens S-adenosylmethionine synthase isoform type-2 Proteins 0.000 title 1
- 102100035947 S-adenosylmethionine synthase isoform type-2 Human genes 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 12
- 125000000592 heterocycloalkyl group Chemical group 0.000 abstract 11
- 125000001475 halogen functional group Chemical group 0.000 abstract 10
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 abstract 5
- 125000000041 C6-C10 aryl group Chemical group 0.000 abstract 5
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 abstract 4
- 125000000217 alkyl group Chemical group 0.000 abstract 4
- 150000001875 compounds Chemical class 0.000 abstract 4
- 125000001072 heteroaryl group Chemical group 0.000 abstract 4
- 229910052739 hydrogen Inorganic materials 0.000 abstract 4
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 3
- 125000006706 (C3-C6) carbocyclyl group Chemical group 0.000 abstract 3
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 abstract 3
- 125000001424 substituent group Chemical group 0.000 abstract 3
- 108010034457 5'-methylthioadenosine phosphorylase Proteins 0.000 abstract 2
- 102100034187 S-methyl-5'-thioadenosine phosphorylase Human genes 0.000 abstract 2
- 125000003342 alkenyl group Chemical group 0.000 abstract 2
- 125000003118 aryl group Chemical group 0.000 abstract 2
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 2
- 125000000623 heterocyclic group Chemical group 0.000 abstract 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 2
- 125000004043 oxo group Chemical group O=* 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- -1 -OC1−6-alkyl Chemical group 0.000 abstract 1
- 125000005915 C6-C14 aryl group Chemical group 0.000 abstract 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical group [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 abstract 1
- 102000007357 Methionine adenosyltransferase Human genes 0.000 abstract 1
- 108010007784 Methionine adenosyltransferase Proteins 0.000 abstract 1
- 108010029485 Protein Isoforms Proteins 0.000 abstract 1
- 102000001708 Protein Isoforms Human genes 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 125000000304 alkynyl group Chemical group 0.000 abstract 1
- 125000004452 carbocyclyl group Chemical group 0.000 abstract 1
- 229910052805 deuterium Inorganic materials 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/20—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
- C07D239/80—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
La presente divulgación proporciona compuestos según la fórmula (1), fórmula (2), y sus sales farmacéuticamente aceptables, tautómeros y/o isotopólogos tal como se describe en la divulgación. Los compuestos son inhibidores de la metionina adenosil-transferasa isoforma 2A (MAT2A). También se proporcionan composiciones farmacéuticas y métodos de uso de compuestos para el tratamiento de cánceres, incluidos algunos cánceres en donde el gen codificado metiltioadenosina fosforilasa (MTAP) es eliminado. Reivindicación 1: Un compuesto de acuerdo con la fórmula (1), en donde X¹ es N o CR⁵; X² es N o CR⁶, en donde X¹ y X² no son simultáneamente N; L es O, S, NR, o un enlace; R es H o C₁₋₆-alquilo; R¹ se selecciona del grupo que consiste en C₁₋₆-alquilo, C₂₋₆-alquenilo, C₃₋₆-carbociclilo, -(C₁₋₆-alquilo)(C₃₋₆-carbociclilo) y -(C₁₋₆-alquilo)(C₃₋₆-cicloalquenilo), en donde cualquier alquilo en R¹ es lineal o ramificado, R¹ se sustituye opcionalmente por 1 - 6 halo; y cuando X¹ es N, X² es CR⁶, L es NR o S, R es H, y R¹ es C₁₋₆-alquilo, después R¹ se sustituye por 1 - 6 halo; o cuando L es NR, entonces R y R¹ pueden tomarse juntos en combinación con L para formar un heterocicloalquilo de 3 a 6 miembros (en donde 1 - 4 miembros del anillo se seleccionan independientemente de N, O y S) sustituido opcionalmente por uno o más RA; R² y R³ se seleccionan independientemente del grupo que consiste en C₆₋₁₀-arilo, C₃₋₆-carbociclilo, heteroarilo de 5 a 10 miembros (en donde 1 - 4 miembros del heteroarilo se seleccionan independientemente de N, O y S), y heterocicloalquilo de 3 a 14 miembros (en donde 1 - 4 miembros del heterocicloalquilo se seleccionan independientemente de N, O y S), en donde R² y R³ se sustituyen opcionalmente e independientemente por uno o más sustituyentes que se seleccionan del grupo que consiste en RA, ORA, halo, -N=N-RA, -NRARB, -(C₁₋₆-alquilo)NRARB, -C(O)ORA, -C(O)NRARB, -OC(O)RA, y -CN; R⁴ se selecciona del grupo que consiste en H, C₁₋₆-alquilo, C₁₋₆-alcoxi, C₂₋₆-alquenilo, C₂₋₆-alquinilo, halo, oxo, -CN y -NRCRD; R⁵ se selecciona del grupo que consiste en H, C₁₋₆-alquilo, C₁₋₆-alcoxi, C₂₋₆-alquenilo, C₂₋₆-alquinilo, halo, -CN y NRCRD; R⁶ se selecciona del grupo que consiste en H, C₁₋₆-alquilo (sustituido opcionalmente por uno o más halo), -O(C₁₋₆-alquilo) (sustituido opcionalmente por uno o más halo), -OH, halo, -CN, -(C₁₋₆-alquilo)NRARB y -NRARB; RA y RB se seleccionan independientemente del grupo que consiste en H, -CN, -hidroxi, oxo, C₁₋₆-alquilo, C₁₋₆-alcoxi, C₂₋₆-alquenilo, C₂₋₆-alquinilo, -NH₂, -S(O)₀₋₂-(C₁₋₆-alquilo), -S(O)₀₋₂-(C₆₋₁₀-arilo), -C(O)(C₁₋₆-alquilo), -C(O)(C₃₋₁₄-carbociclilo), -C₃₋₁₄-carbociclilo, -(C₁₋₆-alquilo)(C₃₋₁₄-carbociclilo), C₆₋₁₀-arilo, heterocicloalquilo de 3 a 14 miembros y -(C₁₋₆-alquilo)-(heterocicloalquilo de 3 a 14 miembros) (en donde 1 - 4 miembros del heterocicloalquilo se seleccionan independientemente de N, O y S), y heteroarilo de 5 a 10 miembros (en donde 1 - 4 miembros del heteroarilo se seleccionan independientemente de N, O y S); en donde cada alquilo, alcoxi, alquilo, alquenilo, alquinilo, arilo, carbociclilo, heterocicloalquilo, y la porción heteroarilo de RA y RB se sustituye opcionalmente con uno o más sustituyentes seleccionados del grupo que consiste en deuterio, hidroxi, halo, -NR₂ (en donde cada R se selecciona independientemente del grupo que consiste en C₁₋₆-alquilo, C₂₋₆-alquenilo, C₂₋₆-alquinilo, C₆₋₁₀-arilo, heterocicloalquilo de 3 a 14 miembros y -(C₁₋₆-alquilo)-(heterocicloalquilo de 3 a 14 miembros) (en donde 1 - 4 miembros del anillo se seleccionan independientemente de N, O, y S), y heteroarilo de 5 a 10 miembros (en donde 1 - 4 miembros del heteroarilo se seleccionan independientemente de N, O, y S)), -NHC(O)(OC₁₋₆-alquilo), -NO₂, -CN, oxo, -C(O)OH, -C(O)O(C₁₋₆-alquilo), -C₁₋₆-alquilo-(C₁₋₆-alcoxi), -C(O)NH₂, C₁₋₆-alquilo-C(O)C₁₋₆-alquilo, -OC₁₋₆-alquilo, -Si(C₁₋₆-alquilo)₃, -S(O)₀₋₂-(C₁₋₆-alquilo), C₆₋₁₀-arilo, -(C₁₋₆-alquilo)(C₆₋₁₀-arilo), heterocicloalquilo de 3 a 14 miembros, y -(C₁₋₆-alquilo)-(heterociclo de 3 a 14 miembros) (en donde 1 - 4 miembros del heterociclo se seleccionan independientemente de N, O, y S), y -O(C₆₋₁₄-arilo), en donde cada alquilo, alquenilo, arilo, y heterocicloalquilo se sustituye opcionalmente con uno o más sustituyentes seleccionados del grupo que consiste en hidroxi, -OC₁₋₆-alquilo, halo, -NH₂, -(C₁₋₆-alquilo)NH₂, -C(O)OH, CN, y oxo; RC y RD cada uno se selecciona independientemente de H y C₁₋₆-alquilo; o una sal farmacéuticamente aceptable de este.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862785574P | 2018-12-27 | 2018-12-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR115296A1 true AR115296A1 (es) | 2020-12-16 |
Family
ID=69400626
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP190103901A AR115296A1 (es) | 2018-12-27 | 2019-12-27 | Heterocíclicos inhibidores de mat2a y métodos de uso para el tratamiento del cáncer |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US20220098203A1 (es) |
| EP (1) | EP3902804A1 (es) |
| JP (1) | JP2022516882A (es) |
| KR (1) | KR20220050832A (es) |
| CN (1) | CN113474347A (es) |
| AR (1) | AR115296A1 (es) |
| AU (1) | AU2019414446A1 (es) |
| BR (1) | BR112021012599A2 (es) |
| CA (1) | CA3124678A1 (es) |
| CL (1) | CL2021001722A1 (es) |
| CO (1) | CO2021009882A2 (es) |
| CR (1) | CR20210409A (es) |
| EA (1) | EA202191800A1 (es) |
| IL (1) | IL284324A (es) |
| JO (1) | JOP20210171A1 (es) |
| MA (1) | MA54609A (es) |
| MX (1) | MX2021007833A (es) |
| PE (1) | PE20212303A1 (es) |
| PH (1) | PH12021551493A1 (es) |
| SG (1) | SG11202106627WA (es) |
| TW (1) | TW202039489A (es) |
| WO (1) | WO2020139992A1 (es) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA54452A (fr) | 2018-12-10 | 2022-03-16 | Ideaya Biosciences Inc | Dérivés de 2-oxoquinazoline utilisés en tant qu'inhibiteurs de la méthionine adénosyltransférase 2a |
| MA54608B1 (fr) * | 2018-12-27 | 2023-02-28 | Servier Lab | Inhibiteurs aza-hétérobicycliques de mat2a et procédés d'utilisation pour le traitement du cancer |
| CA3177164A1 (en) * | 2020-04-28 | 2021-11-04 | Peter Sennhenn | Bicyclic kinase inhibitors and uses thereof |
| WO2021259815A1 (en) * | 2020-06-22 | 2021-12-30 | F. Hoffmann-La Roche Ag | Amidopyrimidone derivatives |
| BR112022026105A2 (pt) * | 2020-06-22 | 2023-01-17 | Hoffmann La Roche | Compostos, composições farmacêuticas, método para o tratamento ou prevenção de adenocarcinoma pulmonar, uso de compostos e invenção |
| WO2022052924A1 (zh) * | 2020-09-11 | 2022-03-17 | 上海凌达生物医药有限公司 | 一类含氮稠环类化合物的制备方法和用途 |
| WO2022143864A1 (zh) * | 2020-12-31 | 2022-07-07 | 江苏先声药业有限公司 | 三环类化合物及用途 |
| CN115141202A (zh) * | 2021-03-29 | 2022-10-04 | 武汉人福创新药物研发中心有限公司 | 嘧啶并吡嗪酮化合物及其用途 |
| WO2023066283A1 (en) | 2021-10-20 | 2023-04-27 | Insilico Medicine Ip Limited | Methionine adenosyltransferase 2a (mat2a) inhibitors and uses thereof |
| US20250186444A1 (en) * | 2021-12-21 | 2025-06-12 | Nanjing Chia Tai Tianqing Pharmaceutical Co., Ltd. | Methionine adenosyltransferase 2a heterocyclic inhibitor |
| KR20240138099A (ko) * | 2022-01-26 | 2024-09-20 | 쑤저우 젠하우스 바이오 컴퍼니 리미티드 | Mtap 결실 암을 치료하기 위한 메티오닌 아데노실트랜스퍼라제 2a 억제제 |
| TW202342024A (zh) * | 2022-03-11 | 2023-11-01 | 大陸商賽諾哈勃藥業（成都）有限公司 | 甲硫胺酸腺苷轉移酶抑制劑、其藥物組合物及應用 |
| GB202204913D0 (en) | 2022-04-04 | 2022-05-18 | Cambridge Entpr Ltd | antiviral therapy |
| CA3258709A1 (en) | 2022-06-27 | 2025-03-18 | Cspc Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd | TRICYCLIC COMPOUNDS AND THEIR USES |
| WO2024080788A1 (ko) | 2022-10-13 | 2024-04-18 | 한미약품 주식회사 | 신규한 트리사이클 유도체 화합물 및 이의 용도 |
| CN121241050A (zh) * | 2023-03-06 | 2025-12-30 | 甘李药业股份有限公司 | 一种甲硫氨酸腺苷转移酶2a抑制剂及其医药用途 |
| WO2024255805A1 (zh) * | 2023-06-14 | 2024-12-19 | 南京正大天晴制药有限公司 | 蛋氨酸腺苷转移酶2a杂环抑制剂的晶型、其制备方法及用途 |
| WO2025000265A1 (en) * | 2023-06-28 | 2025-01-02 | Silexon Ai Technology Co., Ltd. | Heterocyclic compounds usefull as sos1 inhibitor |
| WO2025166257A1 (en) | 2024-02-02 | 2025-08-07 | Ideaya Biosciences, Inc. | Amide substituted triheterocyclic guanidino compounds as prmt5 inhibitors |
| WO2025166260A1 (en) | 2024-02-02 | 2025-08-07 | Ideaya Biosciences, Inc. | Amide substituted tricyclic guanidino compounds as prmt5 inhibitors |
| WO2025166229A1 (en) | 2024-02-02 | 2025-08-07 | Ideaya Biosciences, Inc. | Tricyclic amidino compounds as prmt5 inhibitors |
| WO2025166215A1 (en) | 2024-02-02 | 2025-08-07 | Ideaya Biosciences, Inc. | Triheterocyclic guanidino compounds as prmt5 inhibitors |
| WO2025166274A1 (en) | 2024-02-02 | 2025-08-07 | Ideaya Biosciences, Inc. | Tricyclic guanidino compounds as prmt5 inhibitors |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6576420B1 (en) | 1998-06-23 | 2003-06-10 | Regents Of The University Of California | Method for early diagnosis of, and determination of prognosis in, cancer |
| EP1123295B1 (en) * | 1998-10-23 | 2004-09-29 | F. Hoffmann-La Roche Ag | Bicyclic nitrogen heterocycles |
| AU776250B2 (en) * | 1999-10-21 | 2004-09-02 | F. Hoffmann-La Roche Ag | Heteroalkylamino-substituted bicyclic nitrogen heterocycles as inhibitors of P38 protein kinase |
| PA8577501A1 (es) * | 2002-07-25 | 2004-02-07 | Warner Lambert Co | Inhibidores de quinasas |
| US7084270B2 (en) * | 2002-08-14 | 2006-08-01 | Hoffman-La Roche Inc. | Pyrimido compounds having antiproliferative activity |
| US7112676B2 (en) * | 2002-11-04 | 2006-09-26 | Hoffmann-La Roche Inc. | Pyrimido compounds having antiproliferative activity |
| KR20050111636A (ko) * | 2003-04-10 | 2005-11-25 | 에프. 호프만-라 로슈 아게 | 피리미도 화합물 |
| US7897762B2 (en) * | 2006-09-14 | 2011-03-01 | Deciphera Pharmaceuticals, Llc | Kinase inhibitors useful for the treatment of proliferative diseases |
| JP5478488B2 (ja) | 2007-06-20 | 2014-04-23 | メルク・シャープ・アンド・ドーム・コーポレーション | Ｊａｎｕｓキナーゼの阻害剤 |
| CN104418860B (zh) * | 2013-08-20 | 2016-09-07 | 中国科学院广州生物医药与健康研究院 | 嘧啶并杂环类化合物及其药用组合物和应用 |
| UA125852C2 (uk) * | 2016-08-31 | 2022-06-22 | Ле Лаборатуар Сервьє | Інгібітори клітинних метаболічних процесів |
| WO2019029541A1 (zh) * | 2017-08-08 | 2019-02-14 | 南京药捷安康生物科技有限公司 | 成纤维细胞生长因子受体抑制剂及其用途 |
| MX2020010005A (es) * | 2018-03-30 | 2020-10-14 | Agios Pharmaceuticals Inc | Inhibidores heterobiciclicos de mat2a y metodos de uso para el tratamiento del cancer. |
-
2019
- 2019-12-27 CA CA3124678A patent/CA3124678A1/en active Pending
- 2019-12-27 AR ARP190103901A patent/AR115296A1/es not_active Application Discontinuation
- 2019-12-27 MA MA054609A patent/MA54609A/fr unknown
- 2019-12-27 EA EA202191800A patent/EA202191800A1/ru unknown
- 2019-12-27 US US17/418,406 patent/US20220098203A1/en not_active Abandoned
- 2019-12-27 WO PCT/US2019/068653 patent/WO2020139992A1/en not_active Ceased
- 2019-12-27 BR BR112021012599-0A patent/BR112021012599A2/pt not_active Application Discontinuation
- 2019-12-27 CR CR20210409A patent/CR20210409A/es unknown
- 2019-12-27 SG SG11202106627WA patent/SG11202106627WA/en unknown
- 2019-12-27 JP JP2021538125A patent/JP2022516882A/ja active Pending
- 2019-12-27 MX MX2021007833A patent/MX2021007833A/es unknown
- 2019-12-27 PE PE2021001090A patent/PE20212303A1/es unknown
- 2019-12-27 CN CN201980092839.3A patent/CN113474347A/zh active Pending
- 2019-12-27 JO JOP/2021/0171A patent/JOP20210171A1/ar unknown
- 2019-12-27 AU AU2019414446A patent/AU2019414446A1/en not_active Abandoned
- 2019-12-27 EP EP19845797.0A patent/EP3902804A1/en not_active Withdrawn
- 2019-12-27 KR KR1020217023830A patent/KR20220050832A/ko not_active Withdrawn
- 2019-12-27 TW TW108148080A patent/TW202039489A/zh unknown
- 2019-12-27 PH PH1/2021/551493A patent/PH12021551493A1/en unknown
-
2021
- 2021-06-23 IL IL284324A patent/IL284324A/en unknown
- 2021-06-25 CL CL2021001722A patent/CL2021001722A1/es unknown
- 2021-07-27 CO CONC2021/0009882A patent/CO2021009882A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BR112021012599A2 (pt) | 2021-09-08 |
| JOP20210171A1 (ar) | 2023-01-30 |
| CO2021009882A2 (es) | 2021-10-29 |
| IL284324A (en) | 2021-08-31 |
| KR20220050832A (ko) | 2022-04-25 |
| CL2021001722A1 (es) | 2022-02-18 |
| CA3124678A1 (en) | 2020-07-02 |
| PE20212303A1 (es) | 2021-12-10 |
| PH12021551493A1 (en) | 2022-04-11 |
| CN113474347A (zh) | 2021-10-01 |
| TW202039489A (zh) | 2020-11-01 |
| WO2020139992A1 (en) | 2020-07-02 |
| AU2019414446A1 (en) | 2021-07-15 |
| JP2022516882A (ja) | 2022-03-03 |
| SG11202106627WA (en) | 2021-07-29 |
| CR20210409A (es) | 2022-01-24 |
| MA54609A (fr) | 2022-04-06 |
| EA202191800A1 (ru) | 2021-09-13 |
| US20220098203A1 (en) | 2022-03-31 |
| MX2021007833A (es) | 2021-10-26 |
| EP3902804A1 (en) | 2021-11-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR115296A1 (es) | Heterocíclicos inhibidores de mat2a y métodos de uso para el tratamiento del cáncer | |
| AR117544A1 (es) | Heterocíclicos inhibidores de mat2a y métodos de uso para el tratamiento del cáncer | |
| AR115326A1 (es) | Inhibidores heterobicíclicos de mat2a y métodos de uso para tratar el cáncer | |
| AR119046A1 (es) | Inhibidores heterobicíclicos de mat2a y su uso para el tratamiento de diversos tipos de cáncer | |
| AR103064A1 (es) | Compuestos moduladores de fxr (nr1h4) | |
| AR110405A1 (es) | Compuestos | |
| AR109788A1 (es) | Compuestos de benzo[b]tiofeno como agonistas de sting | |
| AR108875A1 (es) | COMPUESTOS HETEROCÍCLICOS COMO INHIBIDORES DE PI3K-g | |
| AR108710A1 (es) | Compuestos modulares de fxr (nr1h4) | |
| DOP2018000187A (es) | Derivados de pirazolo[1,5-a]pirazin-4-ilo | |
| AR103252A1 (es) | Compuestos de quinazolina | |
| AR105845A1 (es) | Compuestos de heteroarilo bicíclicos fusionados como moduladores de la función irak4 | |
| AR094299A1 (es) | Derivados de ftalazin-1(2h)-ona sustituidos | |
| AR108011A1 (es) | Moduladores receptores de estrógenos | |
| AR112338A2 (es) | Arilciclohexiléteres de dihidro-tetraazabenzoazuleno | |
| AR109709A1 (es) | Inhibidores de la fosfatidilinositol 3-quinasa | |
| AR117900A1 (es) | Pirazolopiridinas y triazolopiridinas como inhibidores de a2a / a2b | |
| AR087628A1 (es) | Inhibidores de pde10 de pirimidina | |
| AR099498A1 (es) | Compuestos de triazina y su uso farmacéutico | |
| AR109296A1 (es) | Derivados de oxadiazolopiridina para el uso como inhibidores de ghrelin o-aciltransferasa (goat) | |
| AR109711A1 (es) | Inhibidores de fosfatidilinositol 3-quinasa | |
| AR105975A1 (es) | Sulfonamidas tricílicas limitadas heterocíclicas como agentes contra el cáncer | |
| AR116022A1 (es) | Compuestos heteroaromáticos como inhibidores de vanina | |
| AR102258A1 (es) | Compuestos de quinolina y quinazolina | |
| AR091534A1 (es) | Derivados de sulfonamida y metodos de uso de los mismos para mejorar la farmacocinetica de un farmaco |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |